Related references
Note: Only part of the references are listed.Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
Dazhi Liu et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2018)
Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer
Curtis R. Chong et al.
CLINICAL CANCER RESEARCH (2017)
Recent Advances in Targeting ROS1 in Lung Cancer
Jessica J. Lin et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2017)
Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics
Dearbhaile C. Collins et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2017)
Molecular mechanisms of therapy resistance in solid tumors: chasing moving targets
Laura J. Tafe
VIRCHOWS ARCHIV (2017)
Prevalence and detection of low-allele-fraction variants in clinical cancer samples
Hyun-Tae Shin et al.
NATURE COMMUNICATIONS (2017)
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
Alexander Drilon et al.
CANCER DISCOVERY (2017)
Understanding and targeting resistance mechanisms in NSCLC
Julia Rotow et al.
NATURE REVIEWS CANCER (2017)
EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases
Aria Vaishnavi et al.
CANCER RESEARCH (2017)
Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
Mariangela Russo et al.
CANCER DISCOVERY (2016)
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
A. Drilon et al.
ANNALS OF ONCOLOGY (2016)
Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor
Maria Menichincheri et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
Elena Ardini et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer
Michihiko Kuwano et al.
PHARMACOLOGY & THERAPEUTICS (2016)
Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism
Chengguang Zhao et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer
Ahnah Song et al.
CLINICAL CANCER RESEARCH (2015)
STAT3 the oncogene - still eluding therapy?
Matthew S. Wake et al.
FEBS JOURNAL (2015)
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer
Gorjan Hrustanovic et al.
NATURE MEDICINE (2015)
Activation of RAS family members confers resistance to ROS1 targeting drugs
Marilisa Cargnelutti et al.
ONCOTARGET (2015)
Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells
Chengguang Zhao et al.
ONCOTARGET (2015)
Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells
Ho-June Lee et al.
CANCER CELL (2014)
ROS1 and ALK Fusions in Colorectal Cancer, with Evidence of Intratumoral Heterogeneity for Molecular Drivers
Dara L. Aisner et al.
MOLECULAR CANCER RESEARCH (2014)
Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
Hua Yu et al.
NATURE REVIEWS CANCER (2014)
Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer
Kurtis D. Davies et al.
PLOS ONE (2013)
Response to Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer
Takefumi Komiya et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Kristin Bergethon et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Sandra Misale et al.
NATURE (2012)
RET, ROS1 and ALK fusions in lung cancer
Kengo Takeuchi et al.
NATURE MEDICINE (2012)
MET and KRAS Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors
Virna Cepero et al.
CANCER RESEARCH (2010)
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
Klarisa Rikova et al.
CELL (2007)
Share Paper
